Preclinical: IND/CTA Enabling

Preclinical activity is conducted through all phases of drug development. We recognize that this activity needs to be fully integrated into a regulatory-driven, collaborative drug development strategy. With over 20 years of experience in drug development, we offer specialized preclinical IND/CTA enabling services.

IND- and CTA-enabling studies comprise preclinical pharmacology and manufacturing studies. These allow you to submit a formal application with the FDA or EMA. We accelerate the development of your medicines, de-risk your program, and reduce time to market by leveraging the extensive experience of our scientific and regulatory affairs experts.

Leverage our unique experience in the synthesis of payloads, linkers, and payload-linker chemical intermediate constructs. We enable the rapid generation of structure activity relationships (SAR) of various linker combinations with your new payloads. We identify the most suitable linker for your ADC profile aligned with your preferred design and for optimal stability and function.